http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105264379-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-912 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 2014-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2017-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-105264379-B |
titleOfInvention | Determine kit, device and the purposes of cell sign thing |
abstract | Present document relates to a kind of method for helping to detect the surface abnormalities in the oesophagus of subject, wherein described surface abnormalities are selected from low depauperation (LGD), height depauperation (HGD), asymptomatic adenocarcinoma of esophagus (OAC) and intra-mucosal carcinoma (IMC), and methods described includes:A) cell sample from the subject is provided, wherein the sample includes the cell of the oesophageal surface collected from subject;B) cell at least two label is determined, wherein the label is selected from (i) p53, (ii) c Myc, (iii) AURKA or PLK1 and preferably AURKA and (iv) MyoD and Runx3 methylates;When wherein detecting the abnormal level of at least two kinds of labels, then infer that subject has the increased possibility of surface abnormalities in oesophagus.The invention further relates to some kits, device and purposes. |
priorityDate | 2013-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 288.